drugset
drugset / Trial / NCT00776802

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00776802 ↗

Phase 1/2 Withdrawn La Jolla Pharmaceutical Company
NaSingle-groupOpen-labelTreatment

Summary

Phase 1/2, open-label, dose-escalation study to assess the safety and tolerability of GCS-100 in combination with etoposide and dexamethasone in patients with relapsed or refractory diffuse large B-cell lymphoma.

Timeline

Start
2008-07
Primary completion
2009-04
Completion
2009-04

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject GCS-100 Unknown 80 mg/m2 Intravenous
Subject GCS-100 Unknown 120 mg/m2 Intravenous
Subject GCS-100 Unknown 160 mg/m2 Intravenous
Background Dexamethasone Small molecule 10 mg/m2 —
Background Etoposide Small molecule 100 mg/m2 —

Indications

diffuse large B-cell lymphoma